This Kohl's Board Member 'Noisily Withdrew.' That's Good.
Earlier this month the retailer named its fourth CEO in less than three years, after the board fired chief executive Ashley Buchanan for directing business to an undisclosed romantic partner. Beyond the mess in the C-suite, the stock is down about 45% year-to-date as the company struggles to turn around declining sales in a sector that is an overall disaster.
But the most glaring sign that something's amiss is the resignation of Kohl's board member Christine M. Day, a longtime retail executive who spent 20 years at Starbucks Corp. and was once the CEO of Lululemon. It's not the fact that she quit that should spark concerns, but how she went about it.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
Hologic (HOLX) Reports Q2: Everything You Need To Know Ahead Of Earnings
Medical technology company Hologic (NASDAQ:HOLX) will be reporting earnings this Wednesday afternoon. Here's what investors should know. Hologic met analysts' revenue expectations last quarter, reporting revenues of $1.01 billion, down 1.2% year on year. It was a slower quarter for the company, with a slight miss of analysts' full-year EPS guidance estimates and full-year revenue guidance meeting analysts' expectations. Is Hologic a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Hologic's revenue to be flat year on year at $1.01 billion, slowing from the 2.7% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.05 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Hologic has only missed Wall Street's revenue estimates once over the last two years, exceeding top-line expectations by 0.9% on average. Looking at Hologic's peers in the healthcare equipment and supplies segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Boston Scientific delivered year-on-year revenue growth of 22.8%, beating analysts' expectations by 3.4%, and Intuitive Surgical reported revenues up 21.4%, topping estimates by 3.7%. Boston Scientific traded up 2.9% following the results while Intuitive Surgical was down 1.9%. Read our full analysis of Boston Scientific's results here and Intuitive Surgical's results here. Investors in the healthcare equipment and supplies segment have had steady hands going into earnings, with share prices flat over the last month. Hologic is up 2.8% during the same time and is heading into earnings with an average analyst price target of $69.93 (compared to the current share price of $66.99). Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Sign in to access your portfolio
Yahoo
23 minutes ago
- Yahoo
CONMED (CNMD) Q2 Earnings: What To Expect
Medical tech company CONMED (NYSE:CNMD) will be announcing earnings results this Wednesday after market close. Here's what to look for. CONMED beat analysts' revenue expectations by 2.6% last quarter, reporting revenues of $321.3 million, up 2.9% year on year. It was a very strong quarter for the company, with a solid beat of analysts' full-year EPS guidance estimates and an impressive beat of analysts' EPS estimates. Is CONMED a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting CONMED's revenue to grow 1.9% year on year to $338.3 million, slowing from the 4.5% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.12 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. CONMED has missed Wall Street's revenue estimates three times over the last two years. Looking at CONMED's peers in the healthcare equipment and supplies segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Boston Scientific delivered year-on-year revenue growth of 22.8%, beating analysts' expectations by 3.4%, and Intuitive Surgical reported revenues up 21.4%, topping estimates by 3.7%. Boston Scientific traded up 2.9% following the results while Intuitive Surgical was down 1.9%. Read our full analysis of Boston Scientific's results here and Intuitive Surgical's results here. Investors in the healthcare equipment and supplies segment have had steady hands going into earnings, with share prices flat over the last month. CONMED is down 4% during the same time and is heading into earnings with an average analyst price target of $66.60 (compared to the current share price of $50.02). Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
23 minutes ago
- Yahoo
Kraft Heinz (KHC) Reports Q2: Everything You Need To Know Ahead Of Earnings
Packaged foods company Kraft Heinz (NASDAQ:KHC) will be reporting results this Wednesday before market open. Here's what investors should know. Kraft Heinz met analysts' revenue expectations last quarter, reporting revenues of $6.00 billion, down 6.4% year on year. It was a mixed quarter for the company, with a narrow beat of analysts' EBITDA estimates but full-year EPS guidance missing analysts' expectations. Is Kraft Heinz a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Kraft Heinz's revenue to decline 3.1% year on year to $6.27 billion, in line with the 3.6% decrease it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.64 per share. Heading into earnings, analysts covering the company have grown increasingly bearish with revenue estimates seeing 4 downward revisions over the last 30 days (we track 10 analysts). Looking at Kraft Heinz's peers in the shelf-stable food segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Lamb Weston delivered year-on-year revenue growth of 4%, beating analysts' expectations by 5.7%, and McCormick reported flat revenue, in line with consensus estimates. Lamb Weston traded up 19.3% following the results while McCormick was also up 3.6%. Read our full analysis of Lamb Weston's results here and McCormick's results here. There has been positive sentiment among investors in the shelf-stable food segment, with share prices up 3.8% on average over the last month. Kraft Heinz is up 9.3% during the same time and is heading into earnings with an average analyst price target of $30.18 (compared to the current share price of $28.22). Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
